Sirolimus-Induced Pulmonary Toxicity without Recurrence more than 8 Years after Everolimus Replacement in a Renal Transplant Patient with Recurrent Skin SCC: A Case Report

Abstract

Abstract Background: IP (Interstitial Pneumonitis) is one of the pulmonary complications associated with mTOR-Is (mammalian Target of Rapamycin-Inhibitors). Sirolimus and Everolimus belong to mTOR-Is. According to studies, IP is caused by both. Case presentation: We want to present a case of IP after 50 months of Sirolimus consumption. Sirolimus was discontinued, and Cyclosporine was started. Thirty-seven months later, Everolimus was prescribed as an alternative to Cyclosporine due to the recurrence of skin SCC (Squamous Cell Carcinoma). Fortunately, no respiratory manifestations were seen after more than 8 years of Everolimus consumption. Conclusions: In conclusion, in cases with Sirolimus-induced IP, discontinuation of Sirolimus and replacement with Everolimus are recommended after resolving clinical symptoms and pulmonary lesions.